The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity

Benoit Vingert, Olivier Adotevi, Delphine Patin, Steffen Jung, Protul Shrikant, Ludovic Freyburger, Cheryl Eppolito, Anita Sapoznikov, Mohamed Amessou, Françoise Quintin-Colonna, Wolf Herman Fridman, Ludger Johannes, Eric Tartour

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The non-toxic B-subunit of Shiga toxin (STxB) interacts with the glycolipid Gb3, which is preferentially expressed on dendritic cells (DC) and B cells. After administration of STxB chemically coupled to OVA (STxB-OVA) in mice, we showed that the immunodominant OVA257-264 peptide restricted by kb molecules is specifically presented by CD11c+CD8α - DC, some of them displaying a mature phenotype. Using mice carrying a transgene encoding a diphtheria toxin receptor (DTR) under the control of the murine CD11c promoter, which allows inducible ablation of DC, we showed that DC are required for efficient priming of CTL after STxB-OVA vaccination. Immunization of mice with STxB-OVA induced OVA-specific CD8+ T cells detected ex vivo; these cells were long lasting, since they could be detected even 91 days after the last immunization and were composed of both central and memory T cells. Vaccination of mice with STxB-OVA and STxB coupled to E7, a protein derived from HPV16, inhibited tumor growth in prophylactic and therapeutic experiments. This effect was mainly mediated by CD8+ T cells. STxB therefore appears to be a powerful carrier directly targeting DC in vivo, resulting in a strong and durable CTL response associated with tumor protection.

Original languageEnglish (US)
Pages (from-to)1124-1135
Number of pages12
JournalEuropean Journal of Immunology
Volume36
Issue number5
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Shiga Toxin
Dendritic Cells
Immunity
Antigens
Neoplasms
T-Lymphocytes
Immunization
Vaccination
Glycolipids
Transgenes
B-Lymphocytes
Phenotype
Peptides
Growth
Proteins

Keywords

  • Cancer vaccine
  • Carrier
  • Cytotoxic T lympohocytes
  • Dendritic cell
  • Tumor immunity

ASJC Scopus subject areas

  • Immunology

Cite this

Vingert, B., Adotevi, O., Patin, D., Jung, S., Shrikant, P., Freyburger, L., ... Tartour, E. (2006). The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. European Journal of Immunology, 36(5), 1124-1135. https://doi.org/10.1002/eji.200535443

The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. / Vingert, Benoit; Adotevi, Olivier; Patin, Delphine; Jung, Steffen; Shrikant, Protul; Freyburger, Ludovic; Eppolito, Cheryl; Sapoznikov, Anita; Amessou, Mohamed; Quintin-Colonna, Françoise; Fridman, Wolf Herman; Johannes, Ludger; Tartour, Eric.

In: European Journal of Immunology, Vol. 36, No. 5, 05.2006, p. 1124-1135.

Research output: Contribution to journalArticle

Vingert, B, Adotevi, O, Patin, D, Jung, S, Shrikant, P, Freyburger, L, Eppolito, C, Sapoznikov, A, Amessou, M, Quintin-Colonna, F, Fridman, WH, Johannes, L & Tartour, E 2006, 'The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity', European Journal of Immunology, vol. 36, no. 5, pp. 1124-1135. https://doi.org/10.1002/eji.200535443
Vingert, Benoit ; Adotevi, Olivier ; Patin, Delphine ; Jung, Steffen ; Shrikant, Protul ; Freyburger, Ludovic ; Eppolito, Cheryl ; Sapoznikov, Anita ; Amessou, Mohamed ; Quintin-Colonna, Françoise ; Fridman, Wolf Herman ; Johannes, Ludger ; Tartour, Eric. / The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. In: European Journal of Immunology. 2006 ; Vol. 36, No. 5. pp. 1124-1135.
@article{ae275858171348d79db7377372660d12,
title = "The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity",
abstract = "The non-toxic B-subunit of Shiga toxin (STxB) interacts with the glycolipid Gb3, which is preferentially expressed on dendritic cells (DC) and B cells. After administration of STxB chemically coupled to OVA (STxB-OVA) in mice, we showed that the immunodominant OVA257-264 peptide restricted by kb molecules is specifically presented by CD11c+CD8α - DC, some of them displaying a mature phenotype. Using mice carrying a transgene encoding a diphtheria toxin receptor (DTR) under the control of the murine CD11c promoter, which allows inducible ablation of DC, we showed that DC are required for efficient priming of CTL after STxB-OVA vaccination. Immunization of mice with STxB-OVA induced OVA-specific CD8+ T cells detected ex vivo; these cells were long lasting, since they could be detected even 91 days after the last immunization and were composed of both central and memory T cells. Vaccination of mice with STxB-OVA and STxB coupled to E7, a protein derived from HPV16, inhibited tumor growth in prophylactic and therapeutic experiments. This effect was mainly mediated by CD8+ T cells. STxB therefore appears to be a powerful carrier directly targeting DC in vivo, resulting in a strong and durable CTL response associated with tumor protection.",
keywords = "Cancer vaccine, Carrier, Cytotoxic T lympohocytes, Dendritic cell, Tumor immunity",
author = "Benoit Vingert and Olivier Adotevi and Delphine Patin and Steffen Jung and Protul Shrikant and Ludovic Freyburger and Cheryl Eppolito and Anita Sapoznikov and Mohamed Amessou and Fran{\cc}oise Quintin-Colonna and Fridman, {Wolf Herman} and Ludger Johannes and Eric Tartour",
year = "2006",
month = "5",
doi = "10.1002/eji.200535443",
language = "English (US)",
volume = "36",
pages = "1124--1135",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity

AU - Vingert, Benoit

AU - Adotevi, Olivier

AU - Patin, Delphine

AU - Jung, Steffen

AU - Shrikant, Protul

AU - Freyburger, Ludovic

AU - Eppolito, Cheryl

AU - Sapoznikov, Anita

AU - Amessou, Mohamed

AU - Quintin-Colonna, Françoise

AU - Fridman, Wolf Herman

AU - Johannes, Ludger

AU - Tartour, Eric

PY - 2006/5

Y1 - 2006/5

N2 - The non-toxic B-subunit of Shiga toxin (STxB) interacts with the glycolipid Gb3, which is preferentially expressed on dendritic cells (DC) and B cells. After administration of STxB chemically coupled to OVA (STxB-OVA) in mice, we showed that the immunodominant OVA257-264 peptide restricted by kb molecules is specifically presented by CD11c+CD8α - DC, some of them displaying a mature phenotype. Using mice carrying a transgene encoding a diphtheria toxin receptor (DTR) under the control of the murine CD11c promoter, which allows inducible ablation of DC, we showed that DC are required for efficient priming of CTL after STxB-OVA vaccination. Immunization of mice with STxB-OVA induced OVA-specific CD8+ T cells detected ex vivo; these cells were long lasting, since they could be detected even 91 days after the last immunization and were composed of both central and memory T cells. Vaccination of mice with STxB-OVA and STxB coupled to E7, a protein derived from HPV16, inhibited tumor growth in prophylactic and therapeutic experiments. This effect was mainly mediated by CD8+ T cells. STxB therefore appears to be a powerful carrier directly targeting DC in vivo, resulting in a strong and durable CTL response associated with tumor protection.

AB - The non-toxic B-subunit of Shiga toxin (STxB) interacts with the glycolipid Gb3, which is preferentially expressed on dendritic cells (DC) and B cells. After administration of STxB chemically coupled to OVA (STxB-OVA) in mice, we showed that the immunodominant OVA257-264 peptide restricted by kb molecules is specifically presented by CD11c+CD8α - DC, some of them displaying a mature phenotype. Using mice carrying a transgene encoding a diphtheria toxin receptor (DTR) under the control of the murine CD11c promoter, which allows inducible ablation of DC, we showed that DC are required for efficient priming of CTL after STxB-OVA vaccination. Immunization of mice with STxB-OVA induced OVA-specific CD8+ T cells detected ex vivo; these cells were long lasting, since they could be detected even 91 days after the last immunization and were composed of both central and memory T cells. Vaccination of mice with STxB-OVA and STxB coupled to E7, a protein derived from HPV16, inhibited tumor growth in prophylactic and therapeutic experiments. This effect was mainly mediated by CD8+ T cells. STxB therefore appears to be a powerful carrier directly targeting DC in vivo, resulting in a strong and durable CTL response associated with tumor protection.

KW - Cancer vaccine

KW - Carrier

KW - Cytotoxic T lympohocytes

KW - Dendritic cell

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=33646569995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646569995&partnerID=8YFLogxK

U2 - 10.1002/eji.200535443

DO - 10.1002/eji.200535443

M3 - Article

C2 - 16568496

AN - SCOPUS:33646569995

VL - 36

SP - 1124

EP - 1135

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 5

ER -